Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 5/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.32 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30966621 | 1.00 | ACHE (0.36) | ACHEKCNN4HSP90AA1HSP90AB1L3MBTL1 | |
| SCHEMBL8763114 | 0.84 | TSHR (0.39) | HSP90AA1HSP90AB1L3MBTL1TDP1ALDH1A1 | |
| SCHEMBL1626692 | 0.83 | L3MBTL1 (0.38) | HSP90AA1HSP90AB1L3MBTL1 | |
| SCHEMBL28679019 | 0.82 | CHRM3 (0.35) | ACHEL3MBTL1AR | |
| SCHEMBL7767484 | 0.80 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL3866351 | 0.80 | CA2 (0.34) | HSP90AA1HSP90AB1L3MBTL1 | |
| SCHEMBL3919628 | 0.78 | AR (0.43) | L3MBTL1TDP1ALDH1A1PGRAR | |
| SCHEMBL18567417 | 0.78 | PGR (0.33) | ACHEKCNN4L3MBTL1HDAC3HDAC1 | |
| SCHEMBL3535813 | 0.77 | AR (0.40) | L3MBTL1PGRAR | |
| SCHEMBL13439652 | 0.77 | TDP1 (0.44) | HSP90AA1HSP90AB1TDP1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101166722-A | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH CORP (US) | 2008-04-23 | — | — | CN | claimed |
| EP-1877377-A2 | PROCESS FOR PREPARING 3,3-DISUBSTITUTED OXINDOLES AND THIO-OXINDOLES | Wyeth (US) | 2008-01-16 | — | — | EP | claimed |
| WO-2006118955-A2 | PROCESS FOR PREPARING 3,3-DISUBSTITUTED OXINDOLES AND THIO-OXINDOLES | WYETH (US) | 2006-11-09 | — | — | WO | claimed |
| US-20060247441-A1 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH (US) | 2006-11-02 | — | — | US | claimed |
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2025-05-22 | — | — | US | disclosed |
| EP-4452964-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2024-10-30 | — | — | EP | disclosed |
| CN-118339153-A | Heteroaromatic compounds for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2023117681-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-29 | — | — | WO | disclosed |
| EP-2435410-B1 | LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-2435410-B1 | LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160280661-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160280661-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2016-09-29 | — | — | US | disclosed |
| US-7595338-B2 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595338-B2 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595338-B2 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH (US) | 2009-09-29 | — | — | US | disclosed |
| CN-101522637-A | Benzimidazole derivatives useful for the treatment of vanilloid receptor 1-related disorders | ASTRAZENECA AB (SE) | 2009-09-02 | — | — | CN | disclosed |
| CN-101166722-A | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH CORP (US) | 2008-04-23 | — | — | CN | disclosed |
| EP-1877377-A2 | PROCESS FOR PREPARING 3,3-DISUBSTITUTED OXINDOLES AND THIO-OXINDOLES | Wyeth (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006118955-A2 | PROCESS FOR PREPARING 3,3-DISUBSTITUTED OXINDOLES AND THIO-OXINDOLES | WYETH (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060247441-A1 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | NRAS, KRAS, RB1 | ACHE 2594/4885KCNN4 3497/4885HSP90AA1 2256/4885 |
| US-20060247441-A1 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | TPMT, TH, HTR3C | ACHE 2655/4885KCNN4 1227/4885HSP90AA1 3763/4885 |
| US-20160280661-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | ACHE 1393/4885KCNN4 4689/4885HSP90AA1 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.